Over 60% of myeloid neoplasms (MN) are diagnosed in adults aged ≥60 years, and up to 73% of older patients with MN experience functional impairment before and during chemotherapy. Establishing biomarkers to identify older patients with MN at risk for functional decline and understanding the mechanisms of decline could guide interventions to prevent functional decline. DNA methylation (DNAm) age, a novel and promising biomarker of biological age, may be used to identify older patients at risk for functional decline. DNAm age captures additional information such as exposures and other stressors that make it a better reflection of biological age compared to chronological age. Accelerated DNAm age (DNAm age minus chronological age) is associated with functional decline, frailty, morbidity, and mortality in the general population. Cancer risk is associated with accelerated DNAm age and chemotherapy leads to profound DNAm changes from pre- to post-chemotherapy in older adults with cancer. The literature suggests that DNAm age may be a better indicator of risk for functional decline among older patients with MN than chronological age. DNAm is influenced by exercise which slows the rate of DNAm age increase over time; exercise is also a promising intervention to prevent functional decline in older patients with MN. It is not yet known, however, whether exercise can slow the rate of DNAm age increase or reverse DNAm age in patients with cancer. Understanding exercise-induced epigenetic changes in older patients with MN, a high risk population, is of great clinical significance. The candidate, Dr. Kah Poh Loh, is board-certified in internal medicine, hematology, oncology, and geriatrics. As part of her NCI K99/R00, Dr. Loh has initiated a pilot randomized controlled trial (RCT) to assess the preliminary efficacy of an mHealth exercise intervention versus control on functional status in older patients with MN receiving outpatient chemotherapy over 12 weeks. The GEMSSTAR R03 will allow Dr. Loh to leverage this unique study to investigate 1) to investigate the association of accelerated peripheral blood DNAm age with functional decline in older adults with MN, 2) to explore exercise-induced epigenetic changes in older patients with MN, and 3) to explore the correlation between peripheral blood and bone marrow DNAm ages. The R03 will complement Dr. Loh’s K99/R00 by allowing her to study DNAm age as a novel biomarker of functional decline and the effect of exercise on DNAm on older adults with cancer. In addition, Dr. Loh will be able to expand her training in epigenetics, bioinformatics, and translational research in cancer and aging under the guidance of an excellent mentoring team. Together, Dr. Loh’s R03 and K99/R00 will provide preliminary data for a phase 3 RCT evaluating the effects of a mHealth exercise intervention on functional decline and epigenetic markers. The combined training and research plan will also position Dr. Loh to become one of the few g...